Roth Capital Upgrades Regeneron Pharma (REGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Credit Suisse Starts Regeneron Pharma (REGN) at Neutral
January 20, 2016 6:36 AM ESTCredit Suisse initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Neutral rating and a price target of $552.00.
Analyst Alethia Young commented, "We are initiating coverage of Regeneron with a Neutral rating and a $552 target price. We are still positive on the... More
